MTD of the combination of oxaliplatin and etoposide assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 21 days [clinicaltrials_resource:b3ac95cf363050d009fab57cae2b1a39]

Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Primary outcome [clinicaltrials_vocabulary:primary-outcome]

http://bio2rdf.org/clinicaltrials_resource:b3ac95cf363050d009fab57cae2b1a39

MTD of the combination of oxaliplatin and etoposide assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 21 days [clinicaltrials_resource:b3ac95cf363050d009fab57cae2b1a39]

Bio2RDF uri

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [clinicaltrials:NCT00101205]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

MTD of the combination of oxaliplatin and etoposide assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 21 days [clinicaltrials_resource:b3ac95cf363050d009fab57cae2b1a39]

Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Primary outcome [clinicaltrials_vocabulary:primary-outcome]

http://bio2rdf.org/clinicaltrials_resource:b3ac95cf363050d009fab57cae2b1a39